DIG
UNCY icon

Dauntless Investment Group’s Unicycive Therapeutics UNCY Stock Holding History

Dauntless Investment Group’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Buy
214,000
+66,913
+45% +$494K 0.79% 27
2026
Q1 		$968K Buy
147,087
+57,672
+64% +$378K 0.64% 21
2025
Q4 		$516K Buy
+89,415
New +$477K 0.41% 34

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Dauntless Investment Group's UNCY Position: Q2 2026 in Review

Dauntless Investment Group increased its Unicycive Therapeutics (UNCY) stake by 45% in Q2 2026, buying an estimated $494K and bringing the position to 214,000 shares worth $1M. The position accounts for 0.79% of the portfolio, ranked #27.

Dauntless Investment Group first reported a position in UNCY in Q4 2025 and has held it in 3 quarters since. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Dauntless Investment Group held 214,000 shares of Unicycive Therapeutics worth $1M as of Q2 2026.
  • Dauntless Investment Group bought 66,913 Unicycive Therapeutics shares in Q2 2026, an estimated $494K.
  • Unicycive Therapeutics made up 0.79% of Dauntless Investment Group's portfolio in Q2 2026, its #27 holding.
  • Dauntless Investment Group first reported a position in Unicycive Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Dauntless Investment Group's 13F filing for Q2 2026, filed 13 Aug 2026.